^
    10ms
    A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors (ESMO 2023)
    Plasma symmetric dimethyl arginine (SDMA), the enzymatic product of PRMT5 was significantly reduced (inhibitory rate: 52.8%∼77.4%) at steady state. Conclusions SCR-6920 had a manageable safety profile and further assessments are ongoing to determine the RP2Ds.
    Clinical • P1 data • PK/PD data • Metastases
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    SIM0272
    over1year
    A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=122, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    SIM0272